Novartis Boosts Zolgensma Production Capacity After FDA Clearance
Novartis Gene Therapies is expanding its manufacturing capacity for Zolgensma (onasemnogene abeparvovec) — its disease-modifying gene therapy for spinal muscular atrophy (SMA) — after its commercial licensure approval was approved by the U.S. Food and Drug...
Funding Bolsters Effort to Bring Newborn Screening to Eastern Canada
A CA$414,000 grant was awarded to the Maritimes by Muscular Dystrophy Canada (MDC) and Novartis Pharmaceuticals Canada to further support the implementation of newborn screening for spinal muscular atrophy (SMA). The funding (about $322,600), received by the Maritime...
SadBaby Crowdfunding Aims to Help SMA Families
SadBaby, an organization that raises donations to support children with spinal muscular atrophy (SMA), is launching a crowdfunding platform. The project, based on digital currency donations, intends to gather funds from supporters and investors to help families...HCP — SMA News Today
BioNews Services, LLC
3 W Garden St
Suite 354
Pensacola, FL 32502
Email: [email protected]
Phone: 1-800-936-1363